BioVersys AG

BioVersys switches off bacterial drug resistance, thus reactivating approved antibiotics.

We develop small chemical molecules, which switch off drug resistance on a gene regulatory level within bacteria, so called TRIC’s (Transcriptional Regulator Inhibitory Compounds). Current pipeline: Gram negative and positive bacteria; Tuberculosis.

Website